Now Playing
Opinion|Videos|November 8, 2024
An Overview of HER2 Alterations in NSCLC and Implications for Treatment
Panelists discuss how understanding the distinctions between HER2 overexpression and mutations in NSCLC influences patient care strategies and prognosis, alongside the challenges of biomarker testing methods such as IHC and NGS.
Advertisement
Episodes in this series
- Can you provide an overview of different HER2 alterations in NSCLC? What are the key differences between HER2 overexpression and HER2 mutations in NSCLC, in terms of biology and how we detect them? How do these distinctions impact our approach to patient care?
- How do prognoses and survival outcomes differ for patients with HER2-overexpressing NSCLC vs those with HER2-mutated NSCLC?
- Can you walk us through your biomarker testing practices in NSCLC, particularly for identifying HER2 overexpression vs HER2 mutations? What are the challenges and considerations specific to each testing approach in NSCLC (IHC vs NGS testing)?
- How do you balance the need for comprehensive biomarker testing with the limitations of tissue availability?
Advertisement
Related to this article
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager, showed an 82% PSA50 response rate and 45% ORR at higher doses in heavily pretreated mCRPC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
3
Building out a Radiopharmaceuticals Program in Oncology Care
4
Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression
5